The FDA cleared PrecivityAD2, a blood test from C2N Diagnostics, on August 20, 2026, as the first FDA-cleared Alzheimer's blood test authorized for adults as young as 40 with signs or symptoms of cognitive impairment. For families watching a parent, spouse, or sibling develop memory or thinking problems before age 65, this is the first blood test cleared with their age group explicitly in the label. That distinction matters because younger-onset Alzheimer's has long been diagnosed with tools validated mainly in older adults. The clearance gives families a specific, narrow use case — and a specific set of questions worth bringing to whoever is managing that evaluation.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check eligibility on Healio’s official study page — Use this page to check the study’s participation requirements.
- Read the official guidance from Practicalneurology — Use this primary source to verify the official guidance.
Table of Contents
- What PrecivityAD2 Actually Measures
- Who the Clearance Actually Covers
- How Reliable Is a Result?
- Questions to Bring to a Clinician
- Why This Clearance Changes the Landscape
- Frequently Asked Questions
What PrecivityAD2 Actually Measures
PrecivityAD2 is a blood test that uses high-resolution mass spectrometry to measure plasma amyloid-beta and tau peptide isoforms — two proteins tied to the biology of Alzheimer's disease. It combines those measurements into a single score, the Amyloid Probability Score 2 (APS2), which runs from 0 to 100, as described by Practical Neurology.
That mass-spectrometry approach is different from the immunoassay method used by some competing blood tests. The score itself does not say "Alzheimer's" or "not Alzheimer's." It estimates how likely the person is to have amyloid plaque buildup in the brain, which is one of the defining features doctors look for when confirming the disease. A family can reasonably ask a clinician to explain where a specific APS2 number falls and what it implies before assuming a result settles the question.
Who the Clearance Actually Covers
The FDA's clearance is limited to adults age 40 and older who are already undergoing clinical evaluation for Alzheimer's disease or another possible cause of cognitive decline. Healio Neurology reports that the label explicitly excludes use as a screening test or as a stand-alone diagnostic tool — it must be interpreted alongside a clinical assessment. That boundary matters for younger-onset families specifically.
The Alzheimer's Association estimates roughly 200,000 Americans under age 65 are living with younger-onset Alzheimer's, a population that prior blood tests, validated mainly in older cohorts, did not explicitly cover. A family member in their 40s or 50s showing cognitive symptoms now falls within an age range a cleared test was actually built and labeled for — but only once a clinician has already started a workup, not as something to request on its own. A reasonable question for a clinician: is this patient's situation the kind the test was cleared for — someone already being evaluated for cognitive decline — or would ordering it fall outside that intended use?.
How Reliable Is a Result?
In C2N's validation study of 1,142 symptomatic adults, results were checked against amyloid PET scans or spinal fluid testing, the more invasive methods traditionally used to confirm amyloid pathology. A positive PrecivityAD2 result had a 97.6% positive predictive value, and a negative result had a 93.1% negative predictive value, according to Healio Neurology. In plain terms, a clear positive or clear negative result tracked the confirmatory test closely.
But not every result lands clearly on one side. About 17.3% of participants in that study received an intermediate "likely positive" result, and that category carried only a 77.3% positive predictive value — notably less certain than a clear positive or negative, per the same Healio report. That gap is worth asking about directly: if a result comes back as "likely positive" rather than a clean positive or negative, what does the clinician recommend next — repeat testing, PET imaging, spinal fluid analysis, or a different approach entirely?.
Questions to Bring to a Clinician
Because the test is cleared only as an aid alongside a clinical workup, Practical Neurology notes that families should ask whether any blood result will be paired with cognitive testing, confirmatory PET or spinal fluid testing when indicated, and genetic counseling — rather than treated as a diagnosis by itself. A handful of direct questions can frame that conversation:.
- Is this patient currently in a clinical evaluation for cognitive decline, which is the setting this test is cleared for?
- What specific APS2 score came back, and does it fall in the clear-positive, clear-negative, or intermediate "likely positive" range?
- If the result is "likely positive," what confirmatory test comes next, and on what timeline?
- Will the result be combined with cognitive testing and, if appropriate, genetic counseling — especially relevant for younger-onset cases where inherited gene mutations are more common?
- Since the FDA-cleared version is expected to become available later in 2026, is the clinic using that version or C2N's existing CLIA-validated laboratory version in the meantime, per C2N's own announcement?
Why This Clearance Changes the Landscape
This clearance brings the number of FDA-cleared Alzheimer's blood tests to three, up from zero a year earlier, according to the Alzheimer's Drug Discovery Foundation, an organization that helped fund the underlying research. The foundation frames the expansion as a step toward precision-medicine options for diagnosis — more tools available, with different validation populations and different intended uses.
For younger-onset families specifically, the practical shift is access to a test whose label was written with their age group in mind, rather than extrapolating from data collected mostly in older patients. C2N states the FDA-cleared version is expected to reach clinics later in 2026, while its CLIA-validated laboratory version continues to be offered through the company's own lab until then. A family whose clinician orders the test soon should ask which version is being used, since the distinction affects how the result was validated and reported.
Frequently Asked Questions
Can someone request PrecivityAD2 as a general screening test without symptoms?
No. The FDA clearance limits use to adults 40 and older already undergoing clinical evaluation for cognitive decline; it is not authorized as a screening test.
Does a positive PrecivityAD2 result confirm Alzheimer's disease on its own?
No. The clearance requires the result to be interpreted alongside clinical assessment, not used as a stand-alone diagnostic.
What should happen if a result comes back as "likely positive" instead of a clear positive or negative?
That intermediate category carried only a 77.3% positive predictive value in the validation study, so a clinician would typically pursue confirmatory testing such as PET imaging or spinal fluid analysis rather than treat it as conclusive.
You Might Also Like
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: What Younger-Onset Alzheimer’s Families Should Know About the News
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: What Younger-Onset Alzheimer’s Families Should Know About the News
- PSEN1 Genetic Test When Dementia Symptoms Progress: Cost, Coverage, and Referral Questions
